肿瘤中的异柠檬酸脱氢酶突变:从基础到临床应用
Isocitrate Dehydrogenase Mutations in Cancer: From Bench to Bedside Applications.
异柠檬酸脱氢酶(IDH)突变是多种恶性肿瘤中的关键致癌驱动因素。
ALL SOURCES
Isocitrate Dehydrogenase Mutations in Cancer: From Bench to Bedside Applications.
异柠檬酸脱氢酶(IDH)突变是多种恶性肿瘤中的关键致癌驱动因素。
Recent advances in CAR-MSCs: the new engine of cellular immunotherapy evolution.
近年来,嵌合抗原受体(CAR)技术的发展极大推动了细胞免疫治疗的进步。
CRISPR-based gene disruption and integration of high-avidity, WT1-specific T cell receptors improve antitumor T cell function.
基于TCR的疗法通过以高灵敏度靶向细胞内肿瘤抗原并促进T细胞存活,有可能在癌症患者中诱导持久的临床反应。
Modified Dendritic cells as a therapeutic platform in hematologic malignancies with translational insights from central nervous system tumors.
树突状细胞(DC)疫苗能引发特异性免疫反应,能够精确消除靶细胞。
Successful autologous T cell apheresis in pediatric patients with hematologic malignancies, solid tumors, and brain tumors.
我们报告,auto-MNC 采集标准可应用于一系列儿童肿瘤适应证,从而实现高度成功的采集及后续生产,且各疾病组之间无显著差异。
Preconditioning of radiotherapy enhances efficacy of B7-H3-CAR-T in treating solid tumor models.
我们的结果提示,B7-H3-CAR-T 疗法联合放疗可能是治疗实体瘤的一种有前景的方式。
mRNA vaccines in cancer immunotherapy: current progress and perspectives in solid tumors and hematologic malignancies.
COVID-19大流行期间mRNA疫苗的空前成功加速了基于核酸的治疗方法的发展,尤其是在肿瘤学领域。
Treatment intensity affects immune reconstitution even after childhood cancer not treated with hematopoietic stem cell transplantation.
我们的数据表明,在大多数当前儿科肿瘤治疗后,所研究的免疫学参数可快速恢复。针对高危急性淋巴细胞白血病、急性髓系白血病、髓母细胞瘤和成熟B细胞淋巴瘤的治疗,与相当比例病例的免疫恢复时间延长相关。高治疗强度与免疫恢复延长相关。
Comprehensive analysis of tumor necrosis factor-α-inducible protein 8-like 2 (TIPE2): A potential novel pan-cancer immune checkpoint.
我们的数据表明,TNFAIP8L2可能是一种跨不同肿瘤类型的新型免疫检查点生物标志物,尤其是在LAML、LGG、KIRC和UVM中,并可能进一步作为免疫治疗的潜在靶点。
共 9 条
MEMBER ACCOUNT
登录成功会直接打开下一页。